The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Enrique Alvarez answers some common questions on this new option for MS patients.
Dr. Enrique Alvarez is a graduate of the Medical Scientist Training program at the University of Colorado Denver and completed his neurology residency and neuroimmunology fellowship at Washington University in St. Louis. He brings varied experience in MS and other neurological disorders to the Rocky Mountain MS Center at University of Colorado. He has a special interest in using biomarkers to customize treatments and patient care. He moved to the Denver area with his wife and two children. Most of his free time is spent with his family and his golden retriever, Daisy.